The Fastest Growing Biotechnology Companies

Growth Strategies, Comparative Analyses and Company Profiles

Publication Date	March 2008
Publisher	Business Insights
Product Type	Report
Pages	280
ISBN Number	not applicable
Product Code	RBI00211

Price

£1,995.00
approximately: $3,919 | €2,536

PDF

PRINT £2,045 ($4,017 | €2,599)

Order above formats by FAX

Summary

In recent years, the biopharmaceutical industry has emerged as one of the most important sectors in the Healthcare field. Advances in life sciences have resulted in the drug discovery process becoming more science-intensive, with an increasing emphasis on cross-company collaborations and the exchange of information. However, growing commercial pressures and rising R&D costs have prompted many biotech companies to seek financial support from global Big Pharma corporations through licensing and collaborative R&D deals. Progressive enhancements in integration have subsequently led to traditional pharma companies becoming increasingly dependant upon the technology platforms and approaches adopted by biotech companies.

The Fastest Growing Biotechnology Companies: Growth strategies, comparative analyses and company profiles is a new report published by Business Insights that examines the structure and organization of the biopharmaceutical industry with a detailed analysis of the fastest growing biotechnology companies. This report provides a comparative analysis of growth strategies and reviews the methods used to improve operational efficiency in light of cost pressures, generic competition, complex pricing, regulations, and globalization. This report also explores the levels of interaction and integration between biopharma companies and the wider pharma industry.

Use key indicators to assess the performances of the fastest growing biotech companies, benchmark their most successful strategies and understand major industrial issues with this new report.

Top five reasons to order your copy today

Identify the fastest growing biotech companies over the 2002-06 period, and use detailed company analysis to measure the performances and outlooks of major players including Theravance, ISTA, Palatin, Pharmion, Amylin, Trimeris, ViroPharma, NPS, SIGA and Idenix.
Discover which therapeutic areas have been targeted by the fastest growing biotech companies and determine which strategies they have used to exploit proprietary technologies and intellectual property.
Review the progress of biotech development programs and understand the regulatory status of new products in development, patents held and the current status of marketed products.
Benchmark the strategies of the fastest growing biotech companies with this report's assessment of the effectiveness and wider implications of a host of leading strategic implementations.
Understand how biopharma drug discovery programs are being improved to develop more efficient methods in the screening of new chemical entities (NCEs).

Key issues examined in this report

Biotech losses. Only eleven of the world's top twenty biotechnology companies currently attain a positive net income. This trend is a key industry-wide issue, with companies now attempting to stabilize financial performance.
Developmental uncertainty. Biotherapeutic developments continue to face a high level of uncertainty. A wide array of factors can contribute to the delay or late-stage failure of promising products.
External investment. Time-consuming, risky and expensive biopharma product developments require high levels of investment and investor patience, as market-generated revenues are often late in materializing. Investors often pursue milestone payments, joint ventures, out-licensing deals, or M&A as alternative exit strategies.
Partnership trends. The majority of dedicated biotech companies have attempted to establish strategic alliances, joint ventures and even mergers between themselves and major pharma companies.

Some key findings from this report

Theravance, Inc. is the fastest growing biotechnology company in the world, with a growth rate of 12,456% over the 2002-06 period. However, Theravance also has one of the highest levels of net losses within the industry, highlighting the need to sustain more stable, predictable and stronger financial performance.
ISTA Pharmaceuticals, Inc is the world's second fastest growing biotechnology company, with a growth rate of 11,773% between 2002-06. Palatin Technologies, Inc. is in third position with a growth rate of 6,928% during the same period.
Amylin Pharmaceuticals, Inc. recorded the greatest sales gains over 2002-2006, with an increase of $497.4mn during this period.
The top 10 fastest growing biotechnology companies had a combined R&D expenditure of $734mn in 2006. This constitutes an increase of $324.7mn since 2002, and a five year growth rate of 179%.
Flexible or adaptive clinical trial designs and proprietary Internet applications are helping to bring products to market faster by improving the efficiency of clincial trials. A prominent example of this is MetaTrial's Electronic Data Capture (EDC) software.

Your questions answered...

Who are the fastest growing biotechnology companies in the world?
What is their level of R&D expenditure and how does this compare to their revenues?
What proportion of biotech company revenues are accounted for by marketed products?
What license agreements, joint ventures and partnerships have been established by the fastest growing biotech companies?
How profitable is the biopharmaceutical industry?
What key strategic tactics are being adopted by the fastest growing biotech companies in R&D, product commercialization, cost containment, manufacturing and screening/development of NCEs?
What are the strengths, weaknesses, opportunities and threats to each of the companies profiled within this report?
What is the product pipeline status of major biotech companies?

Content

Executive Summary
- Summary of key findings
- Comparitive analyses of growth strategies
- Theravance, Inc - company profile and analysis
- ISTA Pharmaceuticals - company profile and analysis
- Palatin Technologies - company profile and analysis
- Pharmion Corporation - company profile and analysis
- Amylin Pharmaceuticals - company profile and analysis
- Trimeris, Inc - company profile and analysis
- ViroPharma Inc - company profile and analysis
- NPS Pharmaceuticals - company profile and analysis
- SIGA Technologies, Inc - company profile and analysis
- Idenix Pharmaceuticals - company profile and analysis
Chapter 1 Key findings and industry
- analysis
- Summary
- Overview of the biotechnology sector
- Recent developments
- Current applications
- Structure of the biotechnology industry
- The pharmaceutical-biopharmaceutical relationship
- Emergence of the biopharmaceutical sector
- Characteristics of the biopharmaceutical industry
- Collaborative corporate environment
- Highly technology and intellectual property
- High venture capital investment
- High risk and costs associated with drug development
- Identifying fast growth companies- Methodology
- Purpose and value of the analysis
- Candidates identified as fast growth companies
Chapter 2 Comparitive analyses of growth
- strategies
- Summary
- The Fastest Growing Biopharmaceutical Companies
- The evolving nature of the biopharmaceutical industry
- Comparative analysis of R&D strategies
- Revenue versus R&D expenditure
- Early Phase R&D Strategies
- Late Stage Clinical Development
- Sponsored Research Payment Strategies
- Analysis by Therapeutic Area
- Comparative analysis of commercialization strategies
- Platform positioning
- The modern extended biopharmaceutical enterprise
- Comparative analysis of manufacturing strategies
- Comparion of restructuring and cost containment strategies
- Case Study: Downsizing R&D at Trimeris, Inc
Chapter 3 Theravance, Inc
- Summary
- Company address and contact details
- Company overview and history
- Business profile
- Discussion and analysis of financial data
- Source and details of income
- Review of proprietary technologies
- Patents and proprietary rights
- Strategic approach and positioning
- Strategic approach
- SWOT Analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- Joint ventures, collaborations and M&A activity
- Theravance's collaboration with GlaxoSmithKline (GSK)
- License, development and commercialization agreement with Astellas
- License agreement with AstraZeneca AB
- Product development programs
- Bacterial infections
- Telavancin
- TD-1792
- Respiratory
- Horizon program (formerly beyond Advair)
- Inhaled bifunctional muscarinic anatgonist-beta2 agonist (MABA)
- program
- Inhaled long-acting muscarinic antagonist (LAMA) program
- Gastrointestinal motility disorders
- Research programs
Chapter 4 ISTA Pharmaceuticals, Inc
- Summary
- Company Address and Contact Details
- Company overview and history
- Business profile
- Discussion and analysis of financial data
- Source and details of income
- Review of proprietary technologies
- Patents and proprietary rights
- Strategic approach and positioning
- Strategic approach
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- Joint ventures, collaborations and M&A activity
- Xibrom, Istalol, Bepotastine, Ecabet Sodium, Latanoprost and Iganidipine
- collaborations with Senju
- Vitrase commercialization outside the US
- Collaboration with Otsuka Pharmaceutical
- Marketed products
- Xibrom (bromfenac)
- Istalol
- Vitrase
- Product development programs
- T-Pred (tobramycin and prednisolone acetate combination product)
- Bepotastine
- Ecabet sodium
- Strong steroid product
Chapter 5 Palatin Technologies Inc
- Summary
- Company address and contact details
- Company overview and history
- Business profile
- Discussion and analysis of financial data
- Source and details of income
- Review of proprietary technologies
- Patents and proprietary rights
- Strategic approach and positioning
- Strengths
- Strength in MC expertise
- Weaknesses
- Termination of collaborative agreement with King Pharmaceuticals
- Limited product pipeline portfolio
- Opportunities
- Threats
- Joint ventures, collaborations and M&A activity
- Strategic alliance with AstraZeneca AB
- Collaborative development and marketing agreement with King
- Pharmaceuticals
- Strategic collaboration agreement with Mallinckrodt
- Product development programs
- Bremelanotide (formerly PT-141)
- Male sexual dysfunction (MED)
- Female sexual dysfunction (FSD)
- Development of novel natriuretic receptor compounds
Chapter 6 Pharmion Corporation
- Summary
- Company address and contact details
- Company overview and history
- Business profile
- Discussion and analysis of financial data
- Source and details of income
- Review of proprietary technologies
- Patents and proprietary rights
- Strategic approach and positioning
- Strengths
- Vidaza: potential future growth and revenue opportunities
- Formation of strategic alliances
- Weaknesses
- Lack of manufacturing capabilities
- Opportunities
- Acquisition by Celgene
- Inorganic growth
- FDA approval of Vidaza NDA supplement for IV administration
- Threats
- Litigations
- Intense competition
- Cost containment pressures
- Joint ventures, collaborations and M&A activity
- M&A history
- Acquisition of Cabrellis Pharmaceuticals
- Joint ventures and collaborations
- Marketed products
- Vidaza (azacitidine for injection)
- Thalidomide Pharmion
- Innohep
- Refludan
- Product development programs
- Amrubicin
- Oral azacitidine
- Satraplatin
- MGCD0103
Chapter 7 Amylin Pharmaceuticals, Inc
- Summary
- Company address and contact details
- Company overview and history
- Business profile
- Discussion and analysis of financial data
- Source and details of income
- Review of proprietary technologies
- Patents and proprietary rights
- Strategic approach and positioning
- Strengths
- Strategic alliances
- Byetta
- New management team
- Weaknesses
- Reliance on third party manufacturers
- Narrow customer concentration
- Opportunities
- Exenatide (long acting release) LAR
- INTO obesity program
- Threats
- Competition
- Joint ventures, collaborations and M&A activity
- Joint ventures and collaborations
- Marketed products
- Byetta (exenatide) injection
- Symlin
- Product development programs
- Diabetes product development
- Exenatide LAR program
- Obesity product development program
- Pramlintide
- Pramlintide and Leptin
- Pramlintide PYY
Chapter 8 Trimeris, Inc
- Summary
- Company address and contact details
- Company overview and history
- Business profile
- Discussion, analysis of financial data
- Details of income
- Review of proprietary technologies
- Patents and proprietary rights
- Strategic approach and positioning
- Strengths
- Collaboration with Roche
- Fuzeon
- Weaknesses
- T-1249 on hold
- Opportunities
- HIV drugs market
- TRI-1144
- Strategic shift in the company's focus
- Threats
- Market acceptance of Fuzeon
- Intense competition
- Joint ventures, collaborations and M&A activity
- Joint ventures and collaborations
- Marketed products
- Fuzeon
- Product development programs
- FUZEON
- T-1249
- next generation fusion inhibitor peptide drug candidates
Chapter 9 ViroPharma Inc
- Summary
- Company address and contact details
- Company overview and history
- Business profile
- Discussion and analysis of financial data
- Source and details of income
- Review of proprietary technologies
- Patents and proprietary rights
- Strategic approach and positioning
- Strengths
- Strategic partnerships
- Fast track status
- Weaknesses
- Lack of manufacturing capabilities
- Customer concentration
- Opportunities
- Camvia (maribavir)
- Threats
- Dependence of continued sales of Vancocin
- Joint ventures, collaborations and M&A activity
- Joint ventures and collaborations
- Cytomegalovirus and GlaxoSmithKline
- Hepatitis C and Wyeth
- Vancocin capsules and Eli Lilly
- Picornaviruses and Schering-Plough Corporation
- Marketed products
- Vancocin
- Product development programs
- Camvia (maribavir)
- HCV-796
- NTCD (non-toxigenic C. difficile)
- Antiviral discovery
Chapter 10 NPS Pharmaceuticals Inc
- Summary
- Company Address and Contact Details
- Company overview and history
- Business profile
- Discussion and analysis of financial data
- Source and details of income
- Review of proprietary technologies
- Patents and proprietary rights
- Strategic approach and positioning
- Strategic approach
- Outsource non-core competencies
- Build a diversified pipeline of products addressing a variety of
- medical conditions
- Collaborate or out-license to reduce risk and accelerate the
- commercialization of select product candidates
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- Joint ventures, collaborations and M&A activity
- Joint ventures and collaborations
- Amgen Inc
- AstraZeneca
- GlaxoSmithKline
- Janssen
- Kirin Brewery of Tokyo (pharmaceutical division)
- Nycomed
- Marketed products
- Sensipar/Mimpara (Cinacalcet HCI)
- Preotact (PREOS)
- Product development programs
- Teduglutide (ALX-0600)
- Calcilytics
- Glycine reuptake inhibitors (GlyT-1)
- Metabotropic glutamate receptors (mGluRs)
Chapter 11 SIGA Technologies, Inc
- Summary
- Company address and contact details
- Company overview and history
- Business profile
- Discussion and analysis of financial data
- Source and details of income
- Review of proprietary technologies
- Patents and proprietary rights
- Strategic approach and positioning
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- Joint ventures, collaborations and M&A activity
- Collaborative research and licenses
- Product development programs
- Anti-infectives
- Anti-smallpox drug
- Other antivirals in development
- Junn
- Lassa fever
- Ebola/Marburg
- HTS discovery campaign
- Dengue
- Bunyavirus
- Sortase
Chapter 12 Idenix Pharmaceuticals, Inc
- Summary
- Company address and contact details
- Company overview and history
- Business profile
- Discussion and analysis of financial data
- Source and Details of Income
- Review of proprietary technologies
- Patents and proprietary rights
- Strategic approach and positioning
- Strategic approach
- Focusing on HCV and HIV drug discovery and development
- programs only
- Discontinuation of the HBV franchise
- Trimmed workforce
- SWOT Analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- Joint ventures, collaborations and M&A activity
- Joint ventures and collaborations
- Marketed products
- Tyzeka/Sebivo (telbivudine)
- Product development programs
- IDX-899
- IDX184
Chapter 13 Appendix
- Methodology statement
- Primary Data and Information Gathering
- Secondary data and information gathering
- Market share analysis and market forecast predictions
- Definitions of Product-Life Cycle stages
- Glossary of abbreviations and acronyms
- Index
List of Figures
- Figure 1.1: Evolution of the biopharmaceutical corporation
- Figure 2.2: Analysis of R&D expenditure v revenues, 2006
- Figure 2.3: Sponsored Research Payment Strategies
- Figure 2.4: Sponsored research payment strategies
- Figure 2.5: The principles of the extended enterprise
- Figure 5.6: Disease area focus, Palatin Technologies
- Figure 5.7: Annual product history, Palatin Technologies
- Figure 7.8: Annual product history, Amylin Pharmaceuticals
- Figure 7.9: Product pipeline, Amylin Pharmaceuticals
- Figure 8.10: Annual product history, Trimeris
- Figure 8.11: Product pipeline, Trimeris
- Figure 9.12: Annual product history, ViroPharma
- Figure 10.13: Annual product history, NPS Pharmaceuticals
- Figure 10.14: Product pipeline, NPS
- Figure 10.15: Disease area focus, NPS Pharmaceuticals
- Figure 11.16: Annual product history, SIGA Technologies
- Figure 11.17: Product pipeline, SIGA Technologies
- Figure 12.18: Annual product history, Idenix Pharmaceuticals
- Figure 12.19: Product pipeline, Idenix Pharmaceuticals
List of Tables
- Table 1.1: Top 20 pharmaceutical companies ranked by revenues (2006)
- Table 2.2: Summary analysis of the fastest growing biopharmaceutical companies, 2006 ($m)
- Table 2.3: Fastest growing biopharmaceutical companies by net income/loss from operations, 2002-06 ($m)
- Table 2.4: The top 20 biopharmaceutical companies by revenue in 2006 ($m)
- Table 2.5: Summary analysis of fastest growing biopharmaceutical companies 2006 ($m)
- Table 2.6: Fastest growing biopharmaceutical companies by revenues and % growth, 2002-06 ($m)
- Table 2.7: Fastest growing biopharmaceutical companies by R&D expenditure, 2002-06 ($m)
- Table 2.8: Company Analysis: Proprietary Technology versus Therapeutic Area
- Table 2.9: Fastest growing biopharmaceutical companies by revenues and % growth, 2002-06 ($m)
- Table 2.10: Company analysis by approved marketed product
- Table 3.11: Company address and contact details
- Table 3.12: Theravance Income Statement, 2002-2006 ($ millions)
- Table 3.13: Theravance product development programs
- Table 4.14: Company address and contact details
- Table 4.15: ISTA Income Statement ($ millions 2002-2006)
- Table 4.16: ISTA marketed product sales ($ millions 2005-2006)
- Table 4.17: ISTA product development and pipeline
- Table 5.18: Company address and contact details
- Table 5.19: Palatin Income Statement ($ millions) year ended June 30, 2003-2007
- Table 5.20: Palatin product development and pipeline
- Table 6.21: Company address and contact details
- Table 6.22: Pharmion Income Statement ($ millions 2002-2006)
- Table 6.23: Pharmion marketed product sales ($ millions, 2002-2006)
- Table 6.24: Pharmion product development and pipeline
- Table 7.25: Company address and contact details
- Table 7.26: Amylin Pharmaceuticals Income Statement, ($ millions, 2002-2006)
- Table 7.27: Amylin Pharmaceuticals Income Statement ($ millions, 2002-2006)
- Table 7.28: Amylin Pharmaceuticals product development and pipeline
- Table 8.29: Company address and contact details
- Table 8.30: Trimeris Income Statement ($ millions 2002-2006)
- Table 8.31: Trimeris product development and pipeline
- Table 9.32: Company address and contact details
- Table 9.33: ViroPharma Income Statement ($ millions, 2002-2006)
- Table 9.34: ViroPharma product development and pipeline
- Table 10.35: Company address and contact details
- Table 10.36: NPS Pharmaceuticals Income Statement ($ millions 2002-2006)
- Table 10.37: Marketed products
- Table 10.38: Marketed products
- Table 10.39: NPS Pharmaceuticals product development and pipeline
- Table 11.40: Company address and contact details
- Table 11.41: SIGA Technologies Income Statement ($ millions, 2002-2006)
- Table 11.42: SIGA Technologies- issued patents as of December 31, 2006
- Table 11.43: SIGA Technologies provisional patents and patent applications as of Dec 31, 2006
- Table 11.44: SIGA Technologies product development and pipeline
- Table 12.45: Company address and contact details
- Table 12.46: Idenix Pharmaceuticals Income Statement ($ millions, 2002-2006)
- Table 12.47: Idenix Pharmaceuticals product development and pipeline